For example, brentuximab vedotin, the first marketed ADC drug, incorporates a peptide cleavable linker conjugated to MMAE (Figure 1), selectively binds to tumor cells expressing CD30 antigen for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Here, TNFRSF8 is linked to Hodgkins lymphoma.